Orion’s Virtual Capital Markets Day today at 13.00 EEST – presentation material now available
ORION CORPORATION INVESTOR NEWS 26 MAY 2021 at 10.15 EEST
Orion’s Virtual Capital Markets Day today at 13.00 EEST – presentation material now available
Orion will arrange a virtual Capital Markets Day 2021 for investors, analysts and media today 13:00–16:00 EEST. The presentation material is now available on Orion’s website at https://www.orion.fi/en/cmd-2021
At the event, Orion’s management will provide an update on the company’s strategy and targets, business and research & development projects. The presentations are divided into two main themes which are ‘Creating growth towards 2025 target and beyond’ and ‘Creating long-term value’.
Speakers and programme
| Main theme | Speaker |
| Orion’s strategy and introduction | Timo Lappalainen, President & CEO |
| Creating growth towards 2025 target and beyond | Satu Ahomäki, SVP, Proprietary Products and Commercial Operations |
| Niclas Lindstedt, VP, Animal Health | |
| Virve Laitinen, SVP, Specialty Products | |
| Jari Karlson, CFO
|
|
|
Creating long-term value |
|
| Outi Vaarala, SVP, Research & Development | |
| Liisa Hurme, SVP, Global Operations | |
| Conclusions | Timo Lappalainen, President & CEO |
Participants of the Capital Markets Day are kindly asked to register for the event through this link. Participants will have the opportunity to ask questions from Orion’s management during the event.
Contact person:
Tuukka Hirvonen, Investor Relations, Orion Corporation
Tel. +358 10 426 2721
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion’s net sales in 2020 amounted to EUR 1,078 million and the company had about 3,300 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.